author-photo

Auke Beishuizen

Boston Children's Hospital

61

Papers

715

Citations

Citation Trend

Filter By

Papers (42) Sort By

Journal Conference Others

Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (1)
Assessment of Waldeyer's ring in pediatric and adolescent Hodgkin lymphoma patients-Importance of multimodality imaging: Results from the EuroNet-PHL-C1 trial.

2021 Pediatric Blood & Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group

2020
Show All
- Source
- Cite
- Save
Citations (6)
Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (12)
HL-032: Nivolumab and Brentuximab Vedotin (BV)–Based, Response-Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study

2020 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Een benauwde jongedame tijdens de coronacrisis

2020 Nederlands Tijdschrift voor Geneeskunde
Show All
- Source
- Cite
- Save
Citations (0)
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Liver involvement in pediatric Hodgkin lymphoma: A systematic review by an international collaboration on Staging Evaluation and Response Criteria Harmonization (SEARCH) for Children, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL).

2020 Pediatric Blood & Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
TARC is a specific and sensitive serum marker for classical Hodgkin’s lymphoma in children

2020
Show All
- Source
- Cite
- Save
Citations (0)